For its third fiscal quarter (ending September 30), Vertex Pharmaceuticals Inc (NASDAQ: VRTX) has reported a 10% increase in E.P.S. from $3.63 a year ago to $4.01 in the current quarter. This performance was $0.03 better than the consensus estimate of $3.98. E.P.S. were $13.48 for the latest four quarters through September 30 versus $12.80 for the same period a year ago — an increase of 5%.
Recent Price Action
On 11/6/23, Vertex Pharmaceuticals Inc (NASDAQ: VRTX) stock enjoyed a large increase of 2.5%, closing at $385.76. The stock has been exceptionally strong relative to the market over the last nine months and has risen 8.6% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, VRTX is expected to continue to be a major Value Builder.
Vertex Pharmaceuticals has a current Value Trend Rating of B (Positive). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Vertex Pharmaceuticals has a neutral Appreciation Score of 54 but a good Power Rating of 82, triggering the Positive Value Trend Rating.
Rating Review
In light of this encouraging new earnings information and positive market action we are reviewing our current Overall Rating of B. We would continue to view the shares with optimism pending completion of this review in the next several days.
Be the first to comment